Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: To evaluate the expression of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) by using immunohistochemistry analysis in locoregionally advanced nasopharyngeal carcinoma (NPC) patients receiving cisplatin, fluorouracil, and docetaxel followed by concurrent chemoradiotherapy.
Methods: As part of a previously reported trial, 108 patients were enrolled in this study.
Results: We observed that Epstein-Barr Virus (EBV) antibody levels were associated with PD-1 positive staining in NPC and PD-1 positive staining was identified as an independent prognostic factor for progression-free survival (hazard ratio 0.363, 95% confidence interval 0.134-0.987, P = .047). By contrast, the correlation between the PD-L1 level and hemoglobin, lactate dehydrogenase and high-sensitivity C-reactive protein was not identified. Moreover, high levels of PD-L1 staining were not significantly associated with clinical outcomes.
Conclusion: NPC patients with negative PD-1 staining had a significantly reduced survival outcome. Furthermore, patients with positive PD-1 staining had significantly higher EBV antibody levels.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.25601 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Br J Cancer
September 2025
Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People's Hospital Heyuan Hospital, Heyuan, Guangdong, China.
Background: Locally advanced nasopharyngeal carcinoma (LA-NPC) has a heterogeneous prognosis, with approximately one-fourth of patients experiencing poor outcomes. Studies have explored the application of induction chemoimmunotherapy followed by chemoradiotherapy, but its efficacy was controversial.
Methods: The protocol was registered in the Prospective Register of Systematic Reviews (PROSPERO, CRD42024619387).
Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: where do we stand?
BMJ Oncol
September 2025
Division of Medical Sciences, National Cancer Centre Singapore, Singapore.
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions.
Expert Opin Biol Ther
September 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Introduction: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with most of patients diagnosed at advanced stage. Thus, systemic therapy remains a cornerstone of treatment. In recent years, immunotherapy has changed therapeutic scenario, being investigated also in combination with anti-vascular endothelial growth factor (VEGF) agents.
View Article and Find Full Text PDFIs it a new era for intrahepatic cholangiocarcinoma?
Crit Rev Oncol Hematol
September 2025
Medical Oncology Unit, Department of Molecular and Clinical Sciences, AOU delle Marche, Polytechnic University of Marche, Ancona, Italy. Electronic address:
Intrahepatic cholangiocarcinoma (iCCA) is increasingly considered as a separate entity from other biliary tract cancers (BTCs), due to differences in aetiology, risk factors, pathobiology, anatomical and molecular biology characteristics. Surgery is the only curative option for the ∼ 30 % who are diagnosed with a resectable disease, while liver-directed therapies (LDTs - i.e.
View Article and Find Full Text PDFComparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer.
Cancer Treat Rev
August 2025
Department of Otorhinolaryngology, Head & Neck Surgery, University of Fukui Hospital, Japan.
Aim: To critically review the emerging evidence from two randomised trials-KEYNOTE-689 and NIVOPOSTOP-on perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma, and to elucidate how these positive results may redefine the current and future treatment paradigms.
Methods: We conducted a narrative review comparing the design, patient populations, treatment protocols, and outcomes of KEYNOTE-689 and NIVOPOSTOP. Data sources included ClinicalTrials.